Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Pressemeddelelse

BioStock: Spago Nanomedical starts phase IIa study in endometriosis

Spago Nanomedical

Lund-based Spago Nanomedical has recently been given the go-ahead to initiate a phase IIa study with the product candidate SN132D for the diagnosis of the widespread disease endometriosis. Patient recruitment has already begun and the company expects to be able to include the first patient shortly. BioStock talked to CEO Mats Hansen about the new area and the upcoming study, but also about the SPAGOPIX-01 study in breast cancer that recently was concluded.

Read the full interview with Spago Nanomedical's CEO Mats Hansen at biostock.se:

https://www.biostock.se/en/2022/12/spago-nanomedical-starts-phase-iia-study-in-endometriosis/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.